Abstract
Treatment decision-making can be complex, notably when there are multiple treatments available, with different (probabilities of) benefits and harms, for example, survival and side effects.1 It is precisely in these complex situations that the preferences of the patient are of utmost importance, as the trade-offs of benefits and harms are subjective and concern patients' lives.2 In such trade-offs, shared decision making (SDM) has gained momentum as a strategy to include both the best available evidence and the patient's preferences.3
Original language | English |
---|---|
Article number | bmjebm-2022-112168 |
Pages (from-to) | 291-294 |
Number of pages | 4 |
Journal | BMJ Evidence-Based Medicine |
Volume | 28 |
Issue number | 5 |
Early online date | 26 May 2023 |
DOIs | |
Publication status | Published - 1 Oct 2023 |
Bibliographical note
Funding Information:This study was funded by KWF Kankerbestrijding (UL-12072).
Publisher Copyright:
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.